Invivyd (IVVD) Cash from Operations Growth (1y) (2022 - 2025)
Powered by 
Analysis
Invivyd (IVVD) Cash from Operations Growth (1y) (2022 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 75.53% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 332.04% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 4.87% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | -28.96% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 42.76% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 151.70% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 178.99% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 56.79% |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 58.91% |
| Sep 30, 2025 | 79.91% |
| Jun 30, 2025 | 68.03% |
| Mar 31, 2025 | 57.92% |
| Dec 31, 2024 | 36.51% |
| Sep 30, 2024 | -16.17% |
| Jun 30, 2024 | -11.25% |
| Mar 31, 2024 | -21.93% |
| Dec 31, 2023 | -24.97% |
| Sep 30, 2023 | 37.03% |
| Jun 30, 2023 | 34.85% |
| Mar 31, 2023 | 30.26% |
| Dec 31, 2022 | 35.25% |
| Sep 30, 2022 | -3.56% |
| Jun 30, 2022 | -70.96% |
| Mar 31, 2022 | -148.72% |